
ImpediMed Ltd
ASX:IPD

ImpediMed Ltd?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.04
0.098
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does ImpediMed Ltd hold over its rivals?
What risks and challenges
does ImpediMed Ltd face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of ImpediMed Ltd.
Provide an overview of the primary business activities
of ImpediMed Ltd.
What unique competitive advantages
does ImpediMed Ltd hold over its rivals?
What risks and challenges
does ImpediMed Ltd face in the near future?
Has there been any significant insider trading activity
in ImpediMed Ltd recently?
Summarize the latest earnings call
of ImpediMed Ltd.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for ImpediMed Ltd.
Provide P/S
for ImpediMed Ltd.
Provide P/E
for ImpediMed Ltd.
Provide P/OCF
for ImpediMed Ltd.
Provide P/FCFE
for ImpediMed Ltd.
Provide P/B
for ImpediMed Ltd.
Provide EV/S
for ImpediMed Ltd.
Provide EV/GP
for ImpediMed Ltd.
Provide EV/EBITDA
for ImpediMed Ltd.
Provide EV/EBIT
for ImpediMed Ltd.
Provide EV/OCF
for ImpediMed Ltd.
Provide EV/FCFF
for ImpediMed Ltd.
Provide EV/IC
for ImpediMed Ltd.
Show me price targets
for ImpediMed Ltd made by professional analysts.
What are the Revenue projections
for ImpediMed Ltd?
How accurate were the past Revenue estimates
for ImpediMed Ltd?
What are the Net Income projections
for ImpediMed Ltd?
How accurate were the past Net Income estimates
for ImpediMed Ltd?
What are the EPS projections
for ImpediMed Ltd?
How accurate were the past EPS estimates
for ImpediMed Ltd?
What are the EBIT projections
for ImpediMed Ltd?
How accurate were the past EBIT estimates
for ImpediMed Ltd?
Compare the revenue forecasts
for ImpediMed Ltd with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of ImpediMed Ltd and its key competitors using the latest financial data.
Compare historical revenue growth rates
of ImpediMed Ltd against its competitors.
Analyze the profit margins
(gross, operating, and net) of ImpediMed Ltd compared to its peers.
Compare the P/E ratios
of ImpediMed Ltd against its peers.
Discuss the investment returns and shareholder value creation
comparing ImpediMed Ltd with its peers.
Analyze the financial leverage
of ImpediMed Ltd compared to its main competitors.
Show all profitability ratios
for ImpediMed Ltd.
Provide ROE
for ImpediMed Ltd.
Provide ROA
for ImpediMed Ltd.
Provide ROIC
for ImpediMed Ltd.
Provide ROCE
for ImpediMed Ltd.
Provide Gross Margin
for ImpediMed Ltd.
Provide Operating Margin
for ImpediMed Ltd.
Provide Net Margin
for ImpediMed Ltd.
Provide FCF Margin
for ImpediMed Ltd.
Show all solvency ratios
for ImpediMed Ltd.
Provide D/E Ratio
for ImpediMed Ltd.
Provide D/A Ratio
for ImpediMed Ltd.
Provide Interest Coverage Ratio
for ImpediMed Ltd.
Provide Altman Z-Score Ratio
for ImpediMed Ltd.
Provide Quick Ratio
for ImpediMed Ltd.
Provide Current Ratio
for ImpediMed Ltd.
Provide Cash Ratio
for ImpediMed Ltd.
What is the historical Revenue growth
over the last 5 years for ImpediMed Ltd?
What is the historical Net Income growth
over the last 5 years for ImpediMed Ltd?
What is the current Free Cash Flow
of ImpediMed Ltd?
Discuss the annual earnings per share (EPS)
trend over the past five years for ImpediMed Ltd.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
AU |
![]() |
ImpediMed Ltd
ASX:IPD
|
81m AUD | -2.9 | |
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
228.3B USD | 22.8 |
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
177.1B USD | 59.1 |
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
146.2B USD | 36.1 |
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
140.7B USD | 24.4 |
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
112.8B USD | 14.1 |
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
64.4B USD | 15.4 |
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
52.1B EUR | 15.2 |
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
43B USD | 24.2 |
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.1B CNY | 19.2 |
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
33.5B USD | 26.9 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
AU |
![]() |
ImpediMed Ltd
ASX:IPD
|
Average EV/EBITDA:
25.7
|
N/A | N/A | |
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
22.8
|
12%
|
1.9 |
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
59.1
|
25%
|
2.4 |
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
36.1
|
20%
|
1.8 |
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
24.4
|
12%
|
2 |
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
14.1
|
9%
|
1.6 |
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
15.4
|
12%
|
1.3 |
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
15.2
|
15%
|
1 |
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
24.2
|
11%
|
2.2 |
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
19.2
|
18%
|
1.1 |
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
26.9
|
11%
|
2.4 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.